Initiative for Medicines, Access & Knowledge
@imakglobal.bsky.social
We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
November 15, 2025 at 5:22 PM
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
October 27, 2025 at 11:09 PM
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
October 27, 2025 at 11:05 PM
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
Watch the full exchange here👇
October 27, 2025 at 11:04 PM
Watch the full exchange here👇
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
October 27, 2025 at 11:04 PM
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
Swipe to see how readers are reacting 👇
October 24, 2025 at 1:19 PM
Swipe to see how readers are reacting 👇
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
October 22, 2025 at 3:40 PM
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
October 22, 2025 at 1:05 PM
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
4 in 5 Americans support changes to patent laws to address drug pricing
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
October 21, 2025 at 1:03 PM
4 in 5 Americans support changes to patent laws to address drug pricing
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Did you RSVP to our webinar?
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
October 19, 2025 at 9:01 PM
Did you RSVP to our webinar?
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
October 17, 2025 at 6:13 PM
JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Swipe to see how readers are reacting 👇
October 14, 2025 at 7:45 PM
Swipe to see how readers are reacting 👇
Merck is launching a patent-protected injectable version of Keytruda before biosimilars of the IV version of Keytruda enter the market.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
September 24, 2025 at 9:39 PM
Merck is launching a patent-protected injectable version of Keytruda before biosimilars of the IV version of Keytruda enter the market.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
MedPath unpacked key findings from our latest Overpatented, Overpriced report.
📊Read our report: www.i-mak.org/overpatented/
📄Read MedPath's analysis: trial.medpath.com/news/1926871...
📊Read our report: www.i-mak.org/overpatented/
📄Read MedPath's analysis: trial.medpath.com/news/1926871...
August 27, 2025 at 2:41 PM
MedPath unpacked key findings from our latest Overpatented, Overpriced report.
📊Read our report: www.i-mak.org/overpatented/
📄Read MedPath's analysis: trial.medpath.com/news/1926871...
📊Read our report: www.i-mak.org/overpatented/
📄Read MedPath's analysis: trial.medpath.com/news/1926871...
AbbVie’s strategy is simple: threaten competitors with drawn-out patent lawsuits to force settlement agreements that keep them off the market, all while charging sky-high prices to cancer patients.
August 14, 2025 at 5:25 PM
AbbVie’s strategy is simple: threaten competitors with drawn-out patent lawsuits to force settlement agreements that keep them off the market, all while charging sky-high prices to cancer patients.
Over the six years competitors are delayed, Americans will spend $8 BILLION on AbbVie’s branded Imbruvica.
August 14, 2025 at 5:25 PM
Over the six years competitors are delayed, Americans will spend $8 BILLION on AbbVie’s branded Imbruvica.
Keeping that many competitors off the market is big business.
An FDA study found that when there are six or more generic competitors on the market, drug prices drop more than 95%.
An FDA study found that when there are six or more generic competitors on the market, drug prices drop more than 95%.
August 14, 2025 at 5:25 PM
Keeping that many competitors off the market is big business.
An FDA study found that when there are six or more generic competitors on the market, drug prices drop more than 95%.
An FDA study found that when there are six or more generic competitors on the market, drug prices drop more than 95%.
Zydus isn’t the only competitor AbbVie bullied off the market.
Five other drug companies signed settlement agreements to delay their generic versions of Imbruvica.
Five other drug companies signed settlement agreements to delay their generic versions of Imbruvica.
August 14, 2025 at 5:25 PM
Zydus isn’t the only competitor AbbVie bullied off the market.
Five other drug companies signed settlement agreements to delay their generic versions of Imbruvica.
Five other drug companies signed settlement agreements to delay their generic versions of Imbruvica.
Patent lawsuits can cost millions of dollars and drag on for years. Rather than face a costly legal battle against AbbVie, Zydus signed a settlement agreement to delay the launch of its generic until 2032.
August 14, 2025 at 5:25 PM
Patent lawsuits can cost millions of dollars and drag on for years. Rather than face a costly legal battle against AbbVie, Zydus signed a settlement agreement to delay the launch of its generic until 2032.
When the drug company Zydus began seeking FDA approval for a generic version of Imbruvica, AbbVie asserted 18 of their 98 patents against them.
August 14, 2025 at 5:25 PM
When the drug company Zydus began seeking FDA approval for a generic version of Imbruvica, AbbVie asserted 18 of their 98 patents against them.
AbbVie has amassed 98 patents on Imbruvica, and is using them to bully competitors into signing settlement agreements to keep generic Imbruvica off the market.
August 14, 2025 at 5:25 PM
AbbVie has amassed 98 patents on Imbruvica, and is using them to bully competitors into signing settlement agreements to keep generic Imbruvica off the market.
The patent covering Imbruvica’s main compound is set to expire in 2026. When that happens, competitors *should* be able to enter the market. But that’s not what’s happening.
August 14, 2025 at 5:25 PM
The patent covering Imbruvica’s main compound is set to expire in 2026. When that happens, competitors *should* be able to enter the market. But that’s not what’s happening.
Imbruvica is a life-saving cancer drug marketed by AbbVie.
Its list price has climbed to $220,000 a year.
Its list price has climbed to $220,000 a year.
August 14, 2025 at 5:25 PM
Imbruvica is a life-saving cancer drug marketed by AbbVie.
Its list price has climbed to $220,000 a year.
Its list price has climbed to $220,000 a year.
AbbVie used its patent thicket to block six competitors from launching cheaper versions of a $220,000 cancer drug.
August 14, 2025 at 5:25 PM
AbbVie used its patent thicket to block six competitors from launching cheaper versions of a $220,000 cancer drug.
SEN. BLUMENTHAL: Do all of you agree that reforms in the patent laws would enable lower costs for consumers?
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes
August 13, 2025 at 2:59 PM
SEN. BLUMENTHAL: Do all of you agree that reforms in the patent laws would enable lower costs for consumers?
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes
…Yes